Author: "Payen, Marie‐Christine" / Database: OAIster - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Payen, Marie‐Christine"' showing total 60 results

Start Over Author "Payen, Marie‐Christine" Database OAIster

60 results on '"Payen, Marie‐Christine"'

1. Evaluation and Modelling of the Performance of an Automated SARS-CoV-2 Antigen Assay According to Sample Type, Target Population and Epidemic Trends

Author: Yin, Nicolas, Debuysschere, Cyril, Daubie, Valéry, Hildebrand, Marc, Martin, Charlotte, Curac, Sonja, Ponthieux, Fanny, Payen, Marie-Christine, Vandenberg, Olivier, Hallin, Marie, Yin, Nicolas, Debuysschere, Cyril, Daubie, Valéry, Hildebrand, Marc, Martin, Charlotte, Curac, Sonja, Ponthieux, Fanny, Payen, Marie-Christine, Vandenberg, Olivier, and Hallin, Marie
Abstract: The Lumipulse® G SARS-CoV-2 Ag assay performance was evaluated on prospectively collected saliva and nasopharyngeal swabs (NPS) of recently ill in- and outpatients and according to the estimated viral load. Performances were calculated using RT-PCR positive NPS from patients with symptoms ≤ 7 days and RT-PCR negative NPS as gold standard. In addition, non-selected positive NPS were analyzed to assess the performances on various viral loads. This assay yielded a sensitivity of 93.1% on NPS and 71.4% on saliva for recently ill patients. For NPS with a viral load > 103 RNA copies/mL, sensitivity was 96.4%. A model established on our daily routine showed fluctuations of the performances depending on the epidemic trends but an overall good negative predictive value. Lumipulse® G SARS-CoV-2 assay yielded good performance for an automated antigen detection assay on NPS. Using it for the detection of recently ill patients or to screen high-risk patients could be an interesting alternative to the more expensive RT-PCR., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2022

2. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author: Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, E., Madonsela, G., Magis Escurra, C., Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Šmite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D'Ambrosio, L., van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista
Published: 2021

3. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author: Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, Elena, Madonsela, G., Magis Escurra, Cecile, Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Smite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D’Ambrosio, Lia, Van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, Elena, Madonsela, G., Magis Escurra, Cecile, Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Smite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D’Ambrosio, Lia, Van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista
Published: 2021

4. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author: Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, Elena, Madonsela, G., Magis Escurra, Cecile, Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Smite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D’Ambrosio, Lia, Van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, Elena, Madonsela, G., Magis Escurra, Cecile, Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Smite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D’Ambrosio, Lia, Van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista
Published: 2021

5. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort

Author: Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, Elena, Madonsela, G., Magis Escurra, Cecile, Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Smite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D’Ambrosio, Lia, Van den Boom, Martin, Sotgiu, Giovanni, Migliori, Giovanni Battista, Koirala, S., Borisov, Sergey, Danila, Edvardas, Mariandyshev, A., Shrestha, B., Lukhele, N., Dalcolmo, Margareth Pretti, Shakya, S.R., Miliauskas, S., Kuksa, Liga, Manga, Selene, Aleksa, Alena, Denholm, Justin, Khadka, H.B., Skrahina, Alena, Diktanas, S., Ferrarese, Maurizio, Bruchfeld, Judith, Koleva, A., Piubello, Alberto, Koirala, G.S., Udwadia, Zarir Farokh, Palmero, Domingo Juan, Muñoz Torrico, Marcela, GC, R., Gualano, Gina, Grecu, V.I., Motta, I., Papavasileiou, A., Li, Yang, Hoefsloot, Wouter, Kunst, Heinke, Mazza Stalder, J., Payen, Marie Christine, Akkerman, Onno, Bernal, Enrique, Manfrin, Vinicio, Matteelli, Alberto, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Cadiñanos Loidi, Julen, Cebrian Gallardo, Jose Joaquín, Duarte, Raquel, Escobar Salinas, N., Gomez Rosso, Roscio Gomez, Laniado Laborín, Rafael, Martínez Robles, Elena, Quirós Fernandez, S., Rendón, Adrián, Solovic, Ivan, Tadolini, Marina, Viggiani, Pietro, Belilovski, Evgeny, Boeree, Martin J., Cai, Qingshan, Davidavičienė, Edita, Forsman, L.D., De Los Rios Jefe, Jorge, Drakšienė, J., Duga, A., Elamin, S.E., Filippov, Alexey, Garcia, A., Gaudiesiute, I., Gavazova, B., Gayoso, Regina, Gruslys, V., Jonsson, Jerker, Khimova, Elena, Madonsela, G., Magis Escurra, Cecile, Marchese, Valentina, Matei, M., Moschos, C., Nakčerienė, B., Nicod, L., Palmieri, Fabrizio, Pontarelli, Agostina, Smite, Agnese, Souleymane, Mahamadou Bassirou, Vescovo, Marisa, Zablockis, R., Zhurkin, Dmitry, Alffenaar, Jan Willem, Caminero, Jose A., Codecasa, Luigi Ruffo, García García, José María, Esposito, Susanna R., Saderi, L., Spanevello, Antonio, Visca, Dina, Tiberi, Simon, Pontali, Emanuele, Centis, Rosella, D’Ambrosio, Lia, Van den Boom, Martin, Sotgiu, Giovanni, and Migliori, Giovanni Battista
Published: 2021

6. Performance of Xpert MTB/RIF Ultra for diagnosis of pulmonary and extra-pulmonary tuberculosis, one year of use in a multi-centric hospital laboratory in Brussels, Belgium

Author: Mekkaoui, Leila, Hallin, Marie, Mouchet, Françoise, Payen, Marie-Christine, Maillart, Evelyne, Clevenbergh, Philippe, Georgala, Aspasia, Van den Wijngaert, Sigi, Mekkaoui, Leila, Hallin, Marie, Mouchet, Françoise, Payen, Marie-Christine, Maillart, Evelyne, Clevenbergh, Philippe, Georgala, Aspasia, and Van den Wijngaert, Sigi
Abstract: Among the challenges in controlling tuberculosis, a rapid and accurate diagnostic test for the detection of Mycobacterium tuberculosis complex (MTBc) and its resistance to first line therapies is crucial. We evaluated the performance of the Xpert MTB/RIF Ultra assay (Xpert Ultra) for the rapid detection of MTBc and rifampicin resistance (RR) in 1120 pulmonary and 461 extra-pulmonary clinical specimens and compared it with conventional phenotypic techniques. The Xpert Ultra assay detected MTBc in 223 (14.1%) samples with an overall sensitivity and specificity, using culture as the "gold standard", of 91.1% (95% CI, 85.6-95.1) and 94.5% (95% CI, 93.1-95.6), respectively. The sensitivity of the Xpert Ultra test for smear-negative extra-pulmonary specimens was high (87.1%), even higher than with smear-negative pulmonary specimens (81.8%). But this enhanced sensitivity came with a low overall specificity of smear-negative extra-pulmonary specimens (66.7%). For 73 patients, 79/1423 (3.4%) negative mycobacterial culture samples were found to be positive with Xpert Ultra. Clinical data was necessary to correctly interpret potential false-positive results, especially trace-positive results. Sensitivity of the Xpert Ultra to detect RR compared to drug susceptibility testing was 100% (95% CI, 29.2-100) and specificity was 99.2% (95% CI, 95.8-100). We concluded that the Xpert Ultra test is able to provide a reliable TB diagnosis within a significantly shorter turnaround time than culture. This is especially true for paucibacillary samples such as smear-negative pulmonary specimens and extra-pulmonary specimens., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2021

7. Aortic thrombosis in a patient with COVID-19-associated hyperinflammatory syndrome

Author: Michotte, Naomi, Allard, Stéphane, Payen, Marie-Christine, Dauby, Nicolas, Michotte, Naomi, Allard, Stéphane, Payen, Marie-Christine, and Dauby, Nicolas
Abstract: SCOPUS: no.j, info:eu-repo/semantics/published
Published: 2021

8. TB in the intensive care unit in a low-endemic country

Author: Genderini, Francesco F.G., Dauby, Nicolas, Delforge, Marie-Luce, De Wit, Stéphane, Payen, Marie-Christine, Genderini, Francesco F.G., Dauby, Nicolas, Delforge, Marie-Luce, De Wit, Stéphane, and Payen, Marie-Christine
Abstract: SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2021

9. Model informed dosing of hydroxycholoroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps.

Author: Thémans, Pauline, Dauby, Nicolas, Schrooyen, Loic, Lebout, Faustine, Delforge, Marie-Luce, Nasreddine, Rakan, Libois, Agnès, Payen, Marie-Christine, Konopnicki, Deborah, Wuillaume, Françoise, Lescrainier, Cecile, Verlinden, Veerle, Dogné, Jean-Michel, Hamdani, Jamila, Musuamba, Flora T, Thémans, Pauline, Dauby, Nicolas, Schrooyen, Loic, Lebout, Faustine, Delforge, Marie-Luce, Nasreddine, Rakan, Libois, Agnès, Payen, Marie-Christine, Konopnicki, Deborah, Wuillaume, Françoise, Lescrainier, Cecile, Verlinden, Veerle, Dogné, Jean-Michel, Hamdani, Jamila, and Musuamba, Flora T
Abstract: In the absence of a commonly agreed dosing protocol based on pharmacokinetic (PK) considerations, the dose and treatment duration for hydroxychloroquine (HCQ) in COVID-19 disease currently vary across national guidelines and clinical study protocols. We have used a model-based approach to explore the relative impact of alternative dosing regimens proposed in different dosing protocols for hydroxychloroquine in COVID-19., SCOPUS: ar.j, SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2020

10. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author: Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, Zignol, Matteo, Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo
Abstract: The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries.The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile.A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019. Keywords: Tuberculosis, MDR-TB, Adverse events, Monitoring, Delamanid, Bedaquiline
Published: 2019

11. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author: Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, Zignol, Matteo, Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendon, Adrian, Skrahina, Alena, Šmite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo
Abstract: The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries.The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile.A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019. Keywords: Tuberculosis, MDR-TB, Adverse events, Monitoring, Delamanid, Bedaquiline
Published: 2019

12. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author: Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth Pretti, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendón, Adrián, Skrahina, Alena, Smite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, Van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, Zignol, Matteo, Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth Pretti, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendón, Adrián, Skrahina, Alena, Smite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, Van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo
Abstract: The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries.The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile.A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019. Keywords: Tuberculosis, MDR-TB, Adverse events, Monitoring, Delamanid, Bedaquiline
Published: 2019

13. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author: Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth Pretti, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendón, Adrián, Skrahina, Alena, Smite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, Van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, Zignol, Matteo, Akkerman, Onno, Aleksa, Alena, Alffenaar, Jan Willem, Al-Marzouqi, Nada Hassan, Arias Guillén, Miguel, Belilovski, Evgeny, Bernal, Enrique, Boeree, Martin J., Borisov, Sergey, Bruchfeld, Judith, Cadiñanos Loidi, Julen, Cai, Qingshan, Caminero, Jose A., Cebrian Gallardo, Jose Joaquín, Centis, Rosella, Codecasa, Luigi Ruffo, D’Ambrosio, Lia, Dalcolmo, Margareth Pretti, Danila, Edvardas, Dara, Masoud, Davidavičienė, Edita, Davies Forsman, Lina, De Los Rios Jefe, Jorge, Denholm, Justin, Duarte, Raquel, Elamin, Seifeldin Eltaeb, Ferrarese, Maurizio, Filippov, Alexey, Ganatra, Shashank, Garcia, Ana, García García, José María, Gayoso, Regina, Giraldo Montoya, Angela Maria, Gomez Rosso, Roscio Gomez, Gualano, Gina, Hoefsloot, Wouter, Ilievska Poposka, Biljana, Jonsson, Jerker, Khimova, Elena, Kuksa, Liga, Kunst, Heinke, Laniado Laborín, Rafael, Li, Yang, Magis Escurra, Cecile, Manfrin, Vinicio, Manga, Selene, Marchese, Valentina, Martínez Robles, Elena, Maryandyshev, Andrei, Matteelli, Alberto, Migliori, Giovanni Battista, Mullerpattan, Jai B., Muñoz Torrico, Marcela, Mustafa Hamdan, Hamdan, Nieto Marcos, Magnolia, Noordin, Noorliza Mohamad, Palmero, Domingo Juan, Palmieri, Fabrizio, Payen, Marie Christine, Piubello, Alberto, Pontali, Emanuele, Pontarelli, Agostina, Quirós, Sarai, Rendón, Adrián, Skrahina, Alena, Smite, Agnese, Solovic, Ivan, Sotgiu, Giovanni, Souleymane, Mahamadou Bassirou, Spanevello, Antonio, Stošić, Maja, Tadolini, Marina, Tiberi, Simon, Udwadia, Zarir Farokh, Van den Boom, Martin, Vescovo, Marisa, Viggiani, Pietro, Visca, Dina, Zhurkin, Dmitry, and Zignol, Matteo
Abstract: The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries.The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs.Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile.A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019. Keywords: Tuberculosis, MDR-TB, Adverse events, Monitoring, Delamanid, Bedaquiline
Published: 2019

14. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study

Author: Akkerman, Onno O.W., Payen, Marie-Christine, Akkerman, Onno O.W., and Payen, Marie-Christine
Abstract: The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile. A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2019

15. Dolutegravir as a trigger for DRESS syndrome?

Author: Martin, Charlotte, Payen, Marie-Christine, De Wit, Stéphane, Martin, Charlotte, Payen, Marie-Christine, and De Wit, Stéphane
Abstract: Dolutegravir is an increasingly-used second-generation human immunodeficiency virus integrase strand transfer inhibitor. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described in several patients treated with raltegravir but to our knowledge, there is no previous report of DRESS syndrome associated with dolutegravir., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2018

16. Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis

Author: Tiberi, Simon, Payen, Marie-Christine, Sotgiu, Giovanni, D'Ambrosio, Lia, Centis, Rosella, Alffenaar, Jan Willem, Migliori, Giovanni Battista, Tiberi, Simon, Payen, Marie-Christine, Sotgiu, Giovanni, D'Ambrosio, Lia, Centis, Rosella, Alffenaar, Jan Willem, and Migliori, Giovanni Battista
Abstract: SCOPUS: le.j, info:eu-repo/semantics/published
Published: 2018

17. Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond

Author: D'Ambrosio, Lia, Bothamley, Graham Henry, Caminero Luna, José Antonio, Duarte, Raquel, Guglielmetti, Lorenzo, Muñoz Torrico, Marcela Verónica M., Payen, Marie-Christine, Saavedra Herrera, N., Salazar Lezama, Miguel Ángel M.A., Skrahina, Alena, Tadolini, Marina, Tiberi, Simon, Veziris, Nicolas, Migliori, Giovanni Battista, D'Ambrosio, Lia, Bothamley, Graham Henry, Caminero Luna, José Antonio, Duarte, Raquel, Guglielmetti, Lorenzo, Muñoz Torrico, Marcela Verónica M., Payen, Marie-Christine, Saavedra Herrera, N., Salazar Lezama, Miguel Ángel M.A., Skrahina, Alena, Tadolini, Marina, Tiberi, Simon, Veziris, Nicolas, and Migliori, Giovanni Battista
Abstract: As recommended by the World Health Organization (WHO), optimal management of MDR-TB cases can be ensured by a multi-speciality consultation body known as ‘TB Consilium’. This body usually includes different medical specialities, competences and perspectives (e.g. clinical expertise both for adults and children; surgical, radiological and public health expertise; psychological background and nursing experience, among others), thus lowering the risk of making mistakes – or managing the patients inappropriately, in order to improve their clinical outcomes. At present, several high MDR-TB burden countries in the different WHO regions (and beyond) have introduced TB Consilium-like bodies at the national or subnational level to reach consensus on the best treatment approach for their patients affected by TB. In addition, in countries/settings where a formal system of consultation does not exist, specialized staff from MDR-TB reference centres or international organizations usually spend a considerable amount of their working time responding to phone or e-mail clinical queries on how to manage M/XDR-TB cases. The aim of this manuscript is to describe the different experiences with the TB Consilia both at the international level (European Respiratory Society – ERS/WHO TB Consilium) and in some of the countries where this experience operates successfully in Europe and beyond. The Consilium experiences are described around the following topics: (1) history, aims and focus; (2) management and funding; (3) technical functioning and structure; (4) results achieved. In addition a comparative analysis of the TB Consilia in the different countries has been performed., SCOPUS: sh.j, info:eu-repo/semantics/published
Published: 2018

18. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study

Author: Efsen, Anne Marie A.M.W., Payen, Marie-Christine, Kabeya, Kabamba, Necsoi, Coca Valentina, Efsen, Anne Marie A.M.W., Payen, Marie-Christine, Kabeya, Kabamba, and Necsoi, Coca Valentina
Abstract: Objectives Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART). Results A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5–74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%. Conclusions Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care., 0, SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2018

19. In reply: Synergy between amoxicillin and meropenem/ clavulanate in drug-resistant tuberculosis

Author: Payen, Marie-Christine, De Wit, Stéphane, Payen, Marie-Christine, and De Wit, Stéphane
Abstract: SCOPUS: le.j, info:eu-repo/semantics/published
Published: 2018

20. Prise en charge de la tuberculose multi-résistante en Belgique :aspects thérapeutiques et organisationnels innovants

Author: Van Vooren, Jean-Paul, Clumeck, Nathan, Casimir, Georges, Jacobs, Frédéric, Denis, Olivier, Smeesters, Pierre, Portaels, Françoise, Callens, Steven S., Payen, Marie-Christine, Van Vooren, Jean-Paul, Clumeck, Nathan, Casimir, Georges, Jacobs, Frédéric, Denis, Olivier, Smeesters, Pierre, Portaels, Françoise, Callens, Steven S., and Payen, Marie-Christine
Abstract: La tuberculose est une maladie infectieuse qui reste un problème de santé publique majeur au XXIème siècle. Transmise d’homme à homme par voie aérienne, elle cause chaque année plus de 10.000.000 nouveaux cas dans le monde et est responsable de près de 2.000.000 de décès. Sa répartition est très hétérogène. Son incidence est la plus élevée dans les pays à revenus faibles et moyens. Dans les pays à revenus élevés, la maladie se concentre dans les grandes villes où elle touche préférentiellement les personnes précarisées.Malgré le déploiement de nouveaux outils diagnostiques et la découverte de nouveaux médicaments, l’incidence de la tuberculose ne diminue que très lentement. Les principales raisons de sa persistance sont l’inégalité de l’accès aux soins dans le monde et l’émergence de tuberculoses multi-résistantes.Ces formes résistantes sont plus difficiles à guérir et nécessitent à l’heure actuelle des traitements très longs et grevés d’effets secondaires potentiellement sévères. Dans certains cas, le germe est tellement résistant que la maladie peut s’avérer incurable.Si la tuberculose multi-résistante est beaucoup plus fréquente dans les pays les plus financièrement démunis, elle peut également émerger dans les pays à revenus élevés si les efforts en matière de prévention et de traitement ne sont pas renforcés. Par ailleurs, les mouvements migratoires et, parfois, le tourisme médical, favorisent la dispersion de ces cas de tuberculose multi-résistante partout dans le monde.La première partie de mon travail est consacrée à la description de la tuberculose, l’historique, l’épidémiologie actuelle, la prise en charge diagnostique et thérapeutique et les facteurs médicaux et sociaux responsables de sa persistance.La deuxième partie décrit la problématique de la tuberculose multi-résistante :épidémiologie, dynamique de transmission, prise en charge diagnostique et thérapeutique. Les barrières au contrôle de la tuberculose, en particulier sa forme résistante sont mises, Doctorat en Sciences biomédicales et pharmaceutiques (Médecine), info:eu-repo/semantics/nonPublished
Published: 2018

21. Is systematic screening and treatment for latent tuberculosis infection in HIV patients useful in a low endemic setting?

Author: Maniewski, Ula, Payen, Marie-Christine, Delforge, Marc, De Wit, Stéphane, Maniewski, Ula, Payen, Marie-Christine, Delforge, Marc, and De Wit, Stéphane
Abstract: Objectives: A decreasing incidence of tuberculosis (TB) among HIV patients has been documented in high-income settings and screening for tuberculosis is not systematically performed in many clinics (such as ours). Our objectives are to evaluate whether a same decline of incidence was seen in our Belgian tertiary center and to evaluate whether systematic screening and prophylaxis of tuberculosis should remain part of routine practice. Methods: Between 2005 and 2012, the annual incidence of tuberculosis among adult HIV patients was measured. The impact of demographic characteristics and CD4 nadir on the incidence of active TB was evaluated. Results: Among the 1167 patients who entered the cohort, 42 developed active TB with a significant decrease of annual incidence from 28/1000 patient-years in 2005 to 3/1000 patient-years in 2012. Among the 42 cases, 83% were of sub-Saharan origin. Median CD4 cell count upon HIV diagnosis was significantly lower in TB cases and 60% had a nadir CD4 below 200/μl. Thirty-six percent of incident TB occurred within 14 days after HIV diagnosis. Conclusion: A significant decline of TB incidence in HIV patients was observed. Incident TB occurred mainly in African patients, with low CD4 upon HIV diagnosis. A significant proportion of TB cases were discovered early in follow-up which probably reflects TB already present upon HIV diagnosis. In a low endemic setting, exclusion of active TB upon HIV diagnosis remains a priority and screening for LTBI should focus on HIV patients from high risk groups such as migrants from endemic regions, especially in patients with low CD4 nadir., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2017

22. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study

Author: Borisov, Sergey S.E., Payen, Marie-Christine, Borisov, Sergey S.E., and Payen, Marie-Christine
Abstract: Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and effectiveness of bedaquiline-containing regimens in a large, retrospective, observational study conducted in 25 centres and 15 countries in five continents. 428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDRTB). MDR-TB cases were admitted to hospital for a median (interquartile range (IQR)) 179 (92-280) days and exposed to bedaquiline for 168 (86-180) days. Treatment regimens included, among others, linezolid, moxifloxacin, clofazimine and carbapenems (82.0%, 58.4%, 52.6% and 15.3% of cases, respectively). Sputum smear and culture conversion rates in MDR-TB cases were 63.6% and 30.1%, respectively at 30 days, 81.1% and 56.7%, respectively at 60 days; 85.5% and 80.5%, respectively at 90 days and 88.7% and 91.2%, respectively at the end of treatment. The median (IQR) time to smear and culture conversion was 34 (30-60) days and 60 (33-90) days. Out of 247 culture-confirmed MDR-TB cases completing treatment, 71.3% achieved success (62.4% cured; 8.9% completed treatment), 13.4% died, 7.3% defaulted and 7.7% failed. Bedaquiline was interrupted due to adverse events in 5.8% of cases. A single case died, having electrocardiographic abnormalities that were probably non-bedaquiline related. Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions., 0, SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2017

23. Immune Activation by Mycobacterium tuberculosis in HIV-Infected and -Uninfected Subjects.

Author: Wyndham-Thomas, Chloe, Corbiere, Véronique, Selis, Elodie, Payen, Marie-Christine, Goffard, Jean-Christophe, Van Vooren, Jean-Paul, Mascart, Françoise, Dirix, Violette, Wyndham-Thomas, Chloe, Corbiere, Véronique, Selis, Elodie, Payen, Marie-Christine, Goffard, Jean-Christophe, Van Vooren, Jean-Paul, Mascart, Françoise, and Dirix, Violette
Abstract: This study investigates the influence of Mycobacterium tuberculosis infection on immune activation biomarkers, both in HIV-infected and -uninfected subjects., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2017

24. Isolation unit for multidrug-resistant tuberculosis patients in a low endemic country, a step towards the World Health Organization End TB Strategy

Author: Payen, Marie-Christine, Van Vooren, Jean-Paul, Vandenberg, Olivier, Clumeck, Nathan, De Wit, Stéphane, Payen, Marie-Christine, Van Vooren, Jean-Paul, Vandenberg, Olivier, Clumeck, Nathan, and De Wit, Stéphane
Abstract: Tuberculosis (TB) remains a threat to public health and is the second cause of death due to a single infectious agent after HIV/AIDS. The worldwide distribution of TB is heterogeneous. The incidence is decreasing in most high-income regions, but the situation remains worrying in many parts of the world. The emergence of Mycobacterium tuberculosis strains resistant to key agents used in treatment (rifampin and isoniazid) contributes to TB transmission around the world. To achieve TB elimination, both high and low endemic countries must upscale their efforts to decrease disease transmission and improve cure rates. Management of drug-resistant TB is of particular importance. In this paper, we discuss the different models of care of multidrug-resistant TB (MDR-TB), the ethical considerations and the specific constraints present in high income countries. The management model chosen by the Belgian TB specialists in accordance with public health authorities as well as building of a specific MDR/XDR-TB isolation unit are also discussed., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2017

25. Faster for less: The new 'shorter' regimen for multidrug-resistant tuberculosis

Author: Sotgiu, Giovanni, Dore, Simone, Gaga, Mina, Gualano, Gina, Kunst, Heinke, Payen, Marie-Christine, Roby Arias, Aurora Jazmín, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Tiberi, Simon, Zumla, Alimuddin, Migliori, Giovanni Battista, D'Ambrosio, Lia, Centis, Rosella, Alffenaar, Jan Willem, Caminero, José Antonio, Arbex, Marcos Abdo, Alarcon Guizado, Valentina, Aleksa, Alena, Sotgiu, Giovanni, Dore, Simone, Gaga, Mina, Gualano, Gina, Kunst, Heinke, Payen, Marie-Christine, Roby Arias, Aurora Jazmín, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Tiberi, Simon, Zumla, Alimuddin, Migliori, Giovanni Battista, D'Ambrosio, Lia, Centis, Rosella, Alffenaar, Jan Willem, Caminero, José Antonio, Arbex, Marcos Abdo, Alarcon Guizado, Valentina, and Aleksa, Alena
Abstract: SCOPUS: le.j, info:eu-repo/semantics/published
Published: 2016

26. Comparison of effectiveness and safety of imipenem/clavulanate-versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Author: Tiberi, Simon, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno O.W., Sotgiu, Giovanni, Aleksa, Alena, Artsukevich, Janina, Auchynka, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, D'Ambrosio, Lia, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Centis, Rosella, Migliori, Giovanni Battista, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, José Antonio, Gaga, Mina, Tiberi, Simon, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno O.W., Sotgiu, Giovanni, Aleksa, Alena, Artsukevich, Janina, Auchynka, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, D'Ambrosio, Lia, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Centis, Rosella, Migliori, Giovanni Battista, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, José Antonio, and Gaga, Mina
Abstract: No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to compare the therapeutic contribution of imipenem/clavulanate versus meropenem/clavulanate added to background regimens to treat MDR- and XDR-TB cases. 84 patients treated with imipenem/clavulanate-containing regimens showed a similar median number of antibiotic resistances (8 versus 8) but more fluoroquinolone resistance (79.0% versus 48.9%, p<0.0001) and higher XDR-TB prevalence (67.9% versus 49.0%, p=0.01) in comparison with 96 patients exposed to meropenem/clavulanate-containing regimens. Patients were treated with imipenem/clavulanate- and meropenem/clavulanate-containing regimens for a median (interquartile range) of 187 (60-428) versus 85 (49-156) days, respectively. Statistically significant differences were observed on sputum smear and culture conversion rates (79.7% versus 94.8%, p=0.02 and 71.9% versus 94.8%, p<0.0001, respectively) and on success rates (59.7% versus 77.5%, p=0.03). Adverse events to imipenem/clavulanate and meropenem/clavulanate were reported in 5.4% and 6.5% of cases only. Our study suggests that meropenem/clavulanate is more effective than imipenem/clavulanate in treating MDR/XDR-TB patients., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2016

27. Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

Author: Tiberi, Simon, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno O.W., Sotgiu, Giovanni, Aleksa, Alena, Artsukevich, Janina, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, D'Ambrosio, Lia, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Centis, Rosella, Migliori, Giovanni Battista, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, José Antonio, Gaga, Mina, Tiberi, Simon, Gualano, Gina, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Alarcon Guizado, Valentina, De Lorenzo, Saverio, Roby Arias, Aurora Jazmín, Scardigli, Anna, Akkerman, Onno O.W., Sotgiu, Giovanni, Aleksa, Alena, Artsukevich, Janina, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, D'Ambrosio, Lia, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Payen, Marie-Christine, Piana, Andrea, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Centis, Rosella, Migliori, Giovanni Battista, Arbex, Marcos Abdo, Alarcon Arrascue, Edith, Alffenaar, Jan Willem, Caminero, José Antonio, and Gaga, Mina
Abstract: SCOPUS: le.j, info:eu-repo/semantics/published
Published: 2016

28. Effectiveness and safety of meropenem/ clavulanate-containing regimens in the treatment of MDR- and XDR-TB

Author: Tiberi, Simon, De Lorenzo, Saverio, Gaga, Mina, Gualano, Gina, Roby Arias, Aurora Jazmín, Scardigli, Anna, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Akkerman, Onno O.W., Payen, Marie-Christine, Alarcon Arrascue, Edith, Aleska, Alena, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Sotgiu, Giovanni, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Migliori, Giovanni Battista, D'Ambrosio, Lia, Alarcon Guizado, Valentina, Alffenaar, Jan Willem, Arbex, Marcos Abdo, Caminero, José Antonio, Centis, Rosella, Tiberi, Simon, De Lorenzo, Saverio, Gaga, Mina, Gualano, Gina, Roby Arias, Aurora Jazmín, Scardigli, Anna, Skrahina, Alena, Solovic, Ivan, Sulis, Giorgia, Tadolini, Marina, Akkerman, Onno O.W., Payen, Marie-Christine, Alarcon Arrascue, Edith, Aleska, Alena, Avchinko, Vera, Bonini, Eduardo Henrique, Chong Marín, Felix Antonio, Collahuazo López, Lorena, De Vries, Gérard, Dore, Simone, Kunst, Heinke, Matteelli, Alberto, Sotgiu, Giovanni, Moschos, Charalampos, Palmieri, Fabrizio, Papavasileiou, Apostolos, Spanevello, Antonio, Vargas Vasquez, Dante, Viggiani, Pietro, White, Veronica, Zumla, Alimuddin, Migliori, Giovanni Battista, D'Ambrosio, Lia, Alarcon Guizado, Valentina, Alffenaar, Jan Willem, Arbex, Marcos Abdo, Caminero, José Antonio, and Centis, Rosella
Abstract: No large study has ever evaluated the efficacy, safety and tolerability of meropenem/ clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases. Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6-9) versus 5 (4-6)). Patients were treated with a meropenem/clavulanate-containing regimen for a median (IQR) of 85 (49-156) days. No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment). The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/clavulanate could be active in treating MDR- and XDR-TB cases., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2016

29. Immunological Signatures Identifying Different Stages of Latent Mycobacterium tuberculosis Infection and Discriminating Latent from Active Tuberculosis in Humans

Author: Smits, Kaatje, Corbiere, Véronique, Dirix, Violette, Mekkaoui, Leila, Wyndham-Thomas, Chloe, Libin, Myriam, Dreesman, Alexandra, Loyens, Marc, Payen, Marie-Christine, Singh, Mahavir, Locht, Camille, Mascart, Françoise, Smits, Kaatje, Corbiere, Véronique, Dirix, Violette, Mekkaoui, Leila, Wyndham-Thomas, Chloe, Libin, Myriam, Dreesman, Alexandra, Loyens, Marc, Payen, Marie-Christine, Singh, Mahavir, Locht, Camille, and Mascart, Françoise
Abstract: Objectives: One third of the world population is considered latently infected with Mycobacterium tuberculosis(LTBI) and sterilizing this reservoir of bacteria that may reactivate is required for tuberculosis (TB) elimination. Thegroup of individuals with LTBI is heterogeneous with some of them being more at risk to develop TB disease thanothers. Improved diagnosis of subjects with LTBI is needed, allowing to differentiate subjects with LTBI from thosewith active TB, and to select among LTBI subjects those who are more at risk to develop active TB. We havecharacterized at the cellular level both the quantitative and qualitative T cell responses to different mycobacterialantigens in selected populations of infected subjects in order to identify new biomarkers that could help to identify M.tuberculosis-infected subjects and to stratify them in risk groups for reactivation of the infection.Methods: Lymphoblast frequencies and cytokine production (IFN-γ, TNF-α, IL-2) among CD4+ and CD8+ T cellswere analyzed by flow cytometry after in vitro stimulation with the latency antigen heparin-binding haemagglutinin(HBHA) or early-secreted antigen Target-6 (ESAT-6) of peripheral blood mononuclear cells from clinically wellcharacterized M. tuberculosis-infected humans (28 LTBI, 22 TB disease,12 controls). The LTBI group definedaccording to the Center for Disease Control guidelines was subdivided into QuantiFERON-TB Gold in-Tube (QFT)positive and negative subgroups.Results: Similar to TB patients, QFT+ LTBI subjects had higher proportions of HBHA-induced TNF-αsingle+ CD4+lymphocytes than QFT- LTBI subjects (p<0.05). Compared to LTBI subjects, TB patients had higher frequencies ofESAT-6-induced CD8+ lymphoblasts (p<0.001), higher proportions of ESAT-6-induced IFN-γ+TNF-α+ CD4+ Tlymphocytes (p<0.05), and lower proportions of HBHA-induced IFN-γ+TNF-α+IL-2+ (p<0.05) CD4+ T lymphocytes.Conclusions: These data provide new biomarkers to discriminate active TB from LTBI, and more interestin, info:eu-repo/semantics/published
Published: 2015

30. Acute myocardial infarction following thalidomide treatment for AIDS-related ulcers.

Author: Dauby, Nicolas, Coussement, Julien, Karakike, Eleni, Ungureanu, Claudiu, De Wit, Stéphane, Payen, Marie-Christine, Dauby, Nicolas, Coussement, Julien, Karakike, Eleni, Ungureanu, Claudiu, De Wit, Stéphane, and Payen, Marie-Christine
Abstract: SCOPUS: le.j, info:eu-repo/semantics/published
Published: 2015

31. Salvage regimen containing meropenem plus clavulanic acid for extensive pulmonary XDR-/pre-XDR-TB: a case-series of 16 patients

Author: Union World Conference on Lung Health (45: October 28 - November 1, 2014: Bacelona, Spain), Payen, Marie-Christine, Callens, Steven, Groenen, G., De Arazolla Wouter, O., Mouchet, Françoise, Muylle, Inge, Clumeck, Nathan, De Wit, Stéphane, Union World Conference on Lung Health (45: October 28 - November 1, 2014: Bacelona, Spain), Payen, Marie-Christine, Callens, Steven, Groenen, G., De Arazolla Wouter, O., Mouchet, Françoise, Muylle, Inge, Clumeck, Nathan, and De Wit, Stéphane
Abstract: info:eu-repo/semantics/nonPublished
Published: 2014

32. Meningitis and splenic infarction due to disseminated Mycobacterium genavense infection in an HIV patient case report and review of the literature

Author: Kyrilli, Aglaia, Payen, Marie-Christine, Antoine-Moussiaux, T., De Wit, Stéphane, Clumeck, Nathan, Kyrilli, Aglaia, Payen, Marie-Christine, Antoine-Moussiaux, T., De Wit, Stéphane, and Clumeck, Nathan
Abstract: We report a case of disseminated infection with Mycobacterium genavense in a 58 year old HIV positive woman presenting with fever, diarrhea, abdominal pain and weight loss. She had a striking hepatosplenomegaly, abdominal lymphadenopathy, anaemia and thrombopenia. Direct smears and cultures of blood, stool, sputum, urine and bone marrow were negative for common and opportunistic microorganisms. Splenectomy revealed numerous acid fast bacill. Lumbar puncture also showed acid fast bacilli at direct examination. Specific PCR and 16s rRNA gene sequencing identified M. genavense. The outcome was fatal despite antimycobacterial therapy. M. genavense must be included in the differential diagnosis of fever, weight loss, lymphadenopathy and splenomegaly in immunocompromised patients. Prompt diagnosis is based on molecular biology methods. Empirical therapy, using at least three antimycobacterial agents, including clarithromycin should be introduced in case of high clinical suspicion., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2013

33. Epidemiology of MDR-TB in a belgian infectious diseases unit: A 15 years review

Author: Van Heurck, Roxane, Payen, Marie-Christine, De Wit, Stéphane, Clumeck, Nathan, Van Heurck, Roxane, Payen, Marie-Christine, De Wit, Stéphane, and Clumeck, Nathan
Abstract: Introduction: For the last 20 years the world has seen the emergence of a growing epidemic of MDR-TB, followed by the appearance of XDR-TB. Both require longer, more expensive and more toxic treatments. MDR-TB and especially XDR-TB are associated with a lower cure rate than non MDR-TB. Materials and Methods: We reviewed retrospectively all cases of MDR-and XDR-TB managed at St Pierre University Hospital between 1996 and 2010. Epidemiological, clinical, bacteriological, treatment, follow up and outcome were collected and analysed. Results: We recorded 73 instances of MDR-TB and 11 XDR-TB for a total of 78 patients. All but 4 patients were of non Belgian origin. 10 patients were co-infected with HIV. A median of 4 active drugs (1-5) were used for a median of 448 days (329-616). 41 MDR-TB (56%) and 1 XDR-TB (1%) were considered as cured and 20 are still on treatment. Since 2007, increasing resistance to second line injectable drugs, fluoroquinolones and even linezolid (1 case) is observed. Extensive resistance was mainly found in patients who had previously been mismanaged with second line agents. Conclusions: This study illustrates the growing epidemic of MDR and XDR-TB, it emphasizes the importance of proper diagnosis and adequate management of TB in patients at risk for resistance and stresses the need for new therapies., SCOPUS: re.j, info:eu-repo/semantics/published
Published: 2013

34. Meningitis and splenic infarction due to disseminated Mycobacterium genavense infection in an HIV patient case report and review of the literature

Author: Kyrilli, Aglaia, Payen, Marie-Christine, Antoine-Moussiaux, T., De Wit, Stéphane, Clumeck, Nathan, Kyrilli, Aglaia, Payen, Marie-Christine, Antoine-Moussiaux, T., De Wit, Stéphane, and Clumeck, Nathan
Abstract: We report a case of disseminated infection with Mycobacterium genavense in a 58 year old HIV positive woman presenting with fever, diarrhea, abdominal pain and weight loss. She had a striking hepatosplenomegaly, abdominal lymphadenopathy, anaemia and thrombopenia. Direct smears and cultures of blood, stool, sputum, urine and bone marrow were negative for common and opportunistic microorganisms. Splenectomy revealed numerous acid fast bacill. Lumbar puncture also showed acid fast bacilli at direct examination. Specific PCR and 16s rRNA gene sequencing identified M. genavense. The outcome was fatal despite antimycobacterial therapy. M. genavense must be included in the differential diagnosis of fever, weight loss, lymphadenopathy and splenomegaly in immunocompromised patients. Prompt diagnosis is based on molecular biology methods. Empirical therapy, using at least three antimycobacterial agents, including clarithromycin should be introduced in case of high clinical suspicion., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2013

35. Epidemiology of MDR-TB in a belgian infectious diseases unit: A 15 years review

Author: Van Heurck, Roxane, Payen, Marie-Christine, De Wit, Stéphane, Clumeck, Nathan, Van Heurck, Roxane, Payen, Marie-Christine, De Wit, Stéphane, and Clumeck, Nathan
Abstract: Introduction: For the last 20 years the world has seen the emergence of a growing epidemic of MDR-TB, followed by the appearance of XDR-TB. Both require longer, more expensive and more toxic treatments. MDR-TB and especially XDR-TB are associated with a lower cure rate than non MDR-TB. Materials and Methods: We reviewed retrospectively all cases of MDR-and XDR-TB managed at St Pierre University Hospital between 1996 and 2010. Epidemiological, clinical, bacteriological, treatment, follow up and outcome were collected and analysed. Results: We recorded 73 instances of MDR-TB and 11 XDR-TB for a total of 78 patients. All but 4 patients were of non Belgian origin. 10 patients were co-infected with HIV. A median of 4 active drugs (1-5) were used for a median of 448 days (329-616). 41 MDR-TB (56%) and 1 XDR-TB (1%) were considered as cured and 20 are still on treatment. Since 2007, increasing resistance to second line injectable drugs, fluoroquinolones and even linezolid (1 case) is observed. Extensive resistance was mainly found in patients who had previously been mismanaged with second line agents. Conclusions: This study illustrates the growing epidemic of MDR and XDR-TB, it emphasizes the importance of proper diagnosis and adequate management of TB in patients at risk for resistance and stresses the need for new therapies., SCOPUS: re.j, info:eu-repo/semantics/published
Published: 2013

36. Multi Drug Resistant Tuberculosis (MDR-TB) in HIV Patients in a High Income Country: Experience in a Belgian HIV Tertiary Center

Author: EACS (14: 16-19 October 2013: Brussels, Belgium), Payen, Marie-Christine, Maniewski, U., Delforge, Marie-Luce, De Wit, Stéphane, Clumeck, Nathan, EACS (14: 16-19 October 2013: Brussels, Belgium), Payen, Marie-Christine, Maniewski, U., Delforge, Marie-Luce, De Wit, Stéphane, and Clumeck, Nathan
Abstract: info:eu-repo/semantics/nonPublished
Published: 2013

37. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis

Author: Payen, Marie-Christine, De Wit, Stéphane, Martin, Charlotte, Sergysels, Roger, Muylle, Inge, Vanlaethem, Yves, Clumeck, Nathan, Payen, Marie-Christine, De Wit, Stéphane, Martin, Charlotte, Sergysels, Roger, Muylle, Inge, Vanlaethem, Yves, and Clumeck, Nathan
Abstract: Mycobacterium tuberculosis strains resistant to almost all available anti-tuberculosis drugs are an increasing threat to public health worldwide. Among existing drugs with potential antimycobacterial effects, the combination of meropenem with clavulanate has been shown to have potent in vitro bactericidal activity against extensively drug-resistant tuberculosis (XDR-TB). To explore its potential clinical efficacy, a meropenem-clavulanate-containing salvage regimen was started in six patients with severe pulmonary XDR-TB, in association with the only one or two remaining active second-line drugs. Encouraging preliminary data are detailed and discussed. © 2012 The Union., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2012

38. Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis

Author: Payen, Marie-Christine, De Wit, Stéphane, Martin, Charlotte, Sergysels, Roger, Muylle, Inge, Vanlaethem, Yves, Clumeck, Nathan, Payen, Marie-Christine, De Wit, Stéphane, Martin, Charlotte, Sergysels, Roger, Muylle, Inge, Vanlaethem, Yves, and Clumeck, Nathan
Abstract: Mycobacterium tuberculosis strains resistant to almost all available anti-tuberculosis drugs are an increasing threat to public health worldwide. Among existing drugs with potential antimycobacterial effects, the combination of meropenem with clavulanate has been shown to have potent in vitro bactericidal activity against extensively drug-resistant tuberculosis (XDR-TB). To explore its potential clinical efficacy, a meropenem-clavulanate-containing salvage regimen was started in six patients with severe pulmonary XDR-TB, in association with the only one or two remaining active second-line drugs. Encouraging preliminary data are detailed and discussed. © 2012 The Union., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2012

39. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis

Author: Dauby, Nicolas, Muylle, Inge, Mouchet, Françoise, Sergysels, Roger, Payen, Marie-Christine, Dauby, Nicolas, Muylle, Inge, Mouchet, Françoise, Sergysels, Roger, and Payen, Marie-Christine
Abstract: The combination of meropenem with clavulanate has high antimycobacterial activity in vitro against extensively drug-resistant Mycobacterium tuberculosis strains. We report the successful use of this combination in association with linezolid in the management of an advanced extensively drug-resistant tuberculosis disease with complex second-line drug resistance in a 14-year-old teenager. © 2011 by Lippincott Williams & Wilkins., SCOPUS: ar.j, SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2011

40. Epidemiology of Multi Drug Resistant Tuberculosis (MDR-TB) in a Belgian Infectious Diseases Unit: a 15 year review

Author: Interscience Conference on Antimicrobial Agents and Chemotherapy – ICAAC (51: Sept. 17-20 2011: Chicago, USA), Van Heurck, Roxane, Payen, Marie-Christine, De Wit, Stéphane, Clumeck, Nathan, Interscience Conference on Antimicrobial Agents and Chemotherapy – ICAAC (51: Sept. 17-20 2011: Chicago, USA), Van Heurck, Roxane, Payen, Marie-Christine, De Wit, Stéphane, and Clumeck, Nathan
Abstract: info:eu-repo/semantics/nonPublished
Published: 2011

41. Amikacin-induced hypomagnesaemic tetany complicating multidrug-resistant tuberculosis treatment.

Author: Dauby, Nicolas, Payen, Marie-Christine, Dauby, Nicolas, and Payen, Marie-Christine
Abstract: Letter, SCOPUS: le.j, info:eu-repo/semantics/published
Published: 2010

42. Four cases of XDR-Tuberculosis treated with meropem-Clavulanate

Author: Interscience Conference on Antimicrobial Agents and Chemotherapy – ICAAC (50: September 12-15, 2010: Boston, USA), Payen, Marie-Christine, Martin, Charlotte, Antoine-Moussiaux, T., De Wit, Stéphane, Clumeck, Nathan, Interscience Conference on Antimicrobial Agents and Chemotherapy – ICAAC (50: September 12-15, 2010: Boston, USA), Payen, Marie-Christine, Martin, Charlotte, Antoine-Moussiaux, T., De Wit, Stéphane, and Clumeck, Nathan
Abstract: info:eu-repo/semantics/nonPublished
Published: 2010

43. Lipids, lipodystrophy, and AIDS

Author: Ducobu, Jean, Payen, Marie-Christine, Ducobu, Jean, and Payen, Marie-Christine
Abstract: The widespread use of combined antiretroviral therapies has greatly reduced morbidity and mortality in HIV-infected patients. Although the success of combination therapy has created hope for long-term treatment, the extensive use of these highly active antiretroviral therapies (HAART) has also uncovered previously uncharacterized adverse drug reactions., SCOPUS: ch.b, info:eu-repo/semantics/published
Published: 2004

44. Lipides et SIDA

Author: Ducobu, Jean, Payen, Marie-Christine, Ducobu, Jean, and Payen, Marie-Christine
Abstract: SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2000

45. Lipides et SIDA

Author: Ducobu, Jean, Payen, Marie-Christine, Ducobu, Jean, and Payen, Marie-Christine
Abstract: SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 2000

46. Neovascularization of the optic disc after highly active antiretroviral therapy in an AIDS patient with cytomegalovirus retinitis: A new immune recovery-related ocular disorder?

Author: Postelmans, Laurence, Payen, Marie-Christine, De Wit, Stéphane, Caspers, Laure, Postelmans, Laurence, Payen, Marie-Christine, De Wit, Stéphane, and Caspers, Laure
Abstract: A patient with AIDS and cytomegalovirus (CMV) retinitis developed a massive bilateral peripheral occlusive vasculopathy with a bilateral neovascularization of the optic disc five weeks after the introduction of highly active antiretroviral therapy (HAART). No associate cause of occlusive vasculopathy was found. Occlusive vasculopathy and optic disc neovascularization may be an immune recovery-related ocular disorder., SCOPUS: cp.j, info:eu-repo/semantics/published
Published: 1999

47. Neovascularization of the optic disc after highly active antiretroviral therapy in an AIDS patient with cytomegalovirus retinitis: A new immune recovery-related ocular disorder?

Author: Postelmans, Laurence, Payen, Marie-Christine, De Wit, Stéphane, Caspers, Laure, Postelmans, Laurence, Payen, Marie-Christine, De Wit, Stéphane, and Caspers, Laure
Abstract: A patient with AIDS and cytomegalovirus (CMV) retinitis developed a massive bilateral peripheral occlusive vasculopathy with a bilateral neovascularization of the optic disc five weeks after the introduction of highly active antiretroviral therapy (HAART). No associate cause of occlusive vasculopathy was found. Occlusive vasculopathy and optic disc neovascularization may be an immune recovery-related ocular disorder., SCOPUS: cp.j, info:eu-repo/semantics/published
Published: 1999

48. Salvage anti HIV triple therapy with Foscarnet in combination with Nelfinavir and Nevirapine in heavily pretreated patients

Author: 5th Conference on Retrovirus and Opportunistic Infection (February 1-5,1998: Chicago, USA), Gérard, Marcel, De Wit, Stéphane, Sprecher-Goldberger, Suzanne, De Cock, Frédérique, Van Laethem, Yves, Hermans, Philippe, Payen, Marie-Christine, Kabeya, Kabamba, Cassano, P., Clumeck, Nathan, 5th Conference on Retrovirus and Opportunistic Infection (February 1-5,1998: Chicago, USA), Gérard, Marcel, De Wit, Stéphane, Sprecher-Goldberger, Suzanne, De Cock, Frédérique, Van Laethem, Yves, Hermans, Philippe, Payen, Marie-Christine, Kabeya, Kabamba, Cassano, P., and Clumeck, Nathan
Abstract: info:eu-repo/semantics/nonPublished
Published: 1998

49. L’éthique des soins palliatifs à l’épreuve de la réalité: un cas de suicide

Author: 12ème Congrès International sur les Soins aux Malades en Phase Terminale (September 13-17,1998: Montréal, Canada), Diricq, Catherine, Payen, Marie-Christine, De Wit, Stéphane, Clumeck, Nathan, 12ème Congrès International sur les Soins aux Malades en Phase Terminale (September 13-17,1998: Montréal, Canada), Diricq, Catherine, Payen, Marie-Christine, De Wit, Stéphane, and Clumeck, Nathan
Abstract: info:eu-repo/semantics/nonPublished
Published: 1998

50. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS

Author: Payen, Marie-Christine, De Wit, Stéphane, Sommereijns, Bernadette, Clumeck, Nathan, Payen, Marie-Christine, De Wit, Stéphane, Sommereijns, Bernadette, and Clumeck, Nathan
Abstract: Pneumocystis carinii pneumonia (PCP) is the most common opportunistic human immunodeficiency virus (HIV)-related infection, occurring in 85% of HIV infected patients without prophylaxis. Preventive treatment is required when CD4 cell count falls below 200 cells per cubic millimeter. Cotrimoxazole has been shown to be highly effective but alternative drug regimens are often necessary because of the frequent drug hypersensitivity exhibited by HIV infected patients. The aim of this prospective, open, randomized, one-site study, involving HIV-infected patients with a CD4 cell count below 200/mm3, or a percentage under 20%, randomly assigned to receive either dapsone 50 mg daily or Fansidar® one tablet weekly, was to compare the efficacy and safety of these drugs in the primary prophylaxis of PCP. Both dapsone and Fansidar® appear to be safe and effective alternative agents for the prevention of PCP. Their role in Toxoplasma gondii prophylaxis requires further evaluation., SCOPUS: ar.j, info:eu-repo/semantics/published
Published: 1997

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Publication Year Range

Publication Type

Database

Publisher

60 results on '"Payen, Marie‐Christine"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources